Abstract
The immunoglobulin μ intronic enhancer is a potent B cell-specific transcriptional activator. The enhancer is activated by the appropriate combination of transcription factors, amongst which are ets and bHLH proteins. HMGA1 (formerly HMG-I(Y)) is a demonstrated co-activator of the μ enhancer. HMGA1 functions through direct interaction with PU.1, one of the ets proteins critical for enhancer activation. New data demonstrates dominant negative HMGA1 dramatically decreases enhancer activity in B cells. EMSA analysis demonstrated that DN HMGA1 disrupts established PU.1/μ enhancer binding. Similarly, DN HMGA1 blocks μ enhancer binding by Ets-1. In sharp contrast, DN HMGA1 had no effect on binding activity of the ETS DNA binding domains of either PU.1 or Ets-1, or the bHLH-zip protein TFE3, suggesting specificity. Taken together, the data suggest that DN HMGA1 utilizes a novel mechanism to specifically block interaction between ets proteins and μ enhancer DNA, suggesting DN HMGA1 represents a new, highly specific means of regulating μ enhancer activity.
Original language | English |
---|---|
Pages (from-to) | 427-433 |
Number of pages | 7 |
Journal | Biochemical and Biophysical Research Communications |
Volume | 292 |
Issue number | 2 |
DOIs | |
State | Published - 2002 |
Bibliographical note
Funding Information:This work was supported by the Evans Medical Foundation and an Arthritis Foundation Biomedical Sciences Grant to B.S.N. K.M.M. was supported by NIH training Grant T32-CA64070.
Keywords
- Burkitt's lymphoma
- Dominant negative
- ETS transcription factors
- Ets-1
- HMGA1
- PU.1
- μ enhancer
ASJC Scopus subject areas
- Biophysics
- Biochemistry
- Molecular Biology
- Cell Biology